BCL2 and breast cancer: In BCap-37 and ZR-75-30 BC cell lines, emodin reduced the expression of Bcl-2 (B-cell CLL/lymphoma 2) and increased levels of cleaved caspase-3, PARP (poly (ADP-ribose) polymerase), p53, and Bax, resulting in dose- and time-dependent proapoptotic effects [26].